ABEONasdaqPharmaceutical PreparationsFiscal year ends December 31
ABEONA THERAPEUTICS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$4.41−0.02 (-0.45%)
Close on Oct 19, 2026
- Market cap
- $251.58M
- P/E (TTM)
- –
- Dividend yield
- –
ABEONA THERAPEUTICS INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 | FY2013 | FY2012 | FY2011 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| License [Member] | $3.40M | – | – | $0 | $602.00K | $602.00K | – | – | – | 58.4% |
| Product [Member] | $2.42M | – | – | – | – | – | $1.53M | $2.87M | $539.00K | 41.6% |
| Foundation revenues | – | – | – | $2.80M | $0 | $0 | – | – | – | – |
| Royalties [Member] | – | – | – | $202.00K | $235.00K | $287.00K | – | – | – | – |
| License Revenues[Member] | – | – | – | – | $602.00K | – | – | – | – | – |
| Foundation [Member] | – | – | – | $2.80M | – | – | – | – | – | – |
| Foundation Revenues [Member] | – | – | – | $2.80M | – | – | – | – | – | – |
| License and Other Revenues [Member] | – | $3.00M | $10.00M | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Abeona Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.